Glaxo CEO: Price Pressure Continues in United States

The transcript discusses the performance and future outlook of various divisions within a pharmaceutical company. It highlights the respiratory market's challenges and the shift from Advair to new products. The consumer division is on track to achieve 20% margins, with synergies between consumer healthcare and pharmaceuticals. The oncology division is developing new products, focusing on epigenetics and immuno-oncology, with promising future prospects.

What was the expected growth for the respiratory division this year?

How did the performance of new products compare to Advair?

What is the trajectory towards achieving 20% margins in the consumer division?

What are the synergies mentioned between the consumer healthcare division and the pharmaceutical business?

What developments are being made in the oncology area according to the text?